Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ott

Showing results (151-160 of 156) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 156 results.
Hepatology Communications|March 27, 2023
The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitisLars Bossen, Tobias Stemann Lau, Mette Bak Nielsen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 8, 2025
Relative Exchangeable Copper, Exchangeable Copper and Total Copper in the Diagnosis of Wilson DiseaseCamilla Lorenzen, Karen Dons, Clàudia García-Solà, et al.
JHEP Reports : Innovation in Hepatology|March 14, 2026
Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease: Monitoring chelation treatment in Wilson diseasePeter Ott, Thomas Sandahl, Aftab Ala, et al.
The Lancet. Gastroenterology & Hepatology|October 2, 2022
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trialMichael L Schilsky, Anna Czlonkowska, Massimo Zuin, et al.
JHEP Reports : Innovation in Hepatology|August 14, 2024
Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targetsPeter Ott, Thomas Sandahl, Aftab Ala, et al.
Circulation|May 2, 2007
Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations)John D Day, Rahul N Doshi, Peter Belott, et al.
Pageof 16

Showing results (151-160 of 156) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 156 results.
Hepatology Communications|March 27, 2023
The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitisLars Bossen, Tobias Stemann Lau, Mette Bak Nielsen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 8, 2025
Relative Exchangeable Copper, Exchangeable Copper and Total Copper in the Diagnosis of Wilson DiseaseCamilla Lorenzen, Karen Dons, Clàudia García-Solà, et al.
JHEP Reports : Innovation in Hepatology|March 14, 2026
Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease: Monitoring chelation treatment in Wilson diseasePeter Ott, Thomas Sandahl, Aftab Ala, et al.
The Lancet. Gastroenterology & Hepatology|October 2, 2022
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trialMichael L Schilsky, Anna Czlonkowska, Massimo Zuin, et al.
JHEP Reports : Innovation in Hepatology|August 14, 2024
Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: Alignment with recommended targetsPeter Ott, Thomas Sandahl, Aftab Ala, et al.
Circulation|May 2, 2007
Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations)John D Day, Rahul N Doshi, Peter Belott, et al.
Pageof 16